A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis

A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis

This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple doses of NS2 0.5%, NS2 0.5% and Pred Forte® 1%, or Pred Forte® 1%.

Free aldehydes are thought to be related to inflammatory diseases such as uveitis. NS2, a small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.

Inclusion Criteria:

• Non-infectious anterior uveitis
• Grade 1 - Grade 3 anterior chamber cell count
• Subjects must have Intraocular pressure <25 mmHg at baseline and may only administer a maximum of 1 topical medication to control Intraocular pressure in the study eye.
• Visual acuity ≥ 20/200 in the study eye

Exclusion Criteria:

• Severe/serious ocular pathology
• Active intermediate or posterior uveitis.
• Previous anterior uveitis episode in the study eye within 4 weeks of Visit 1
• Oral corticosteroids within 14 days of Visit 1
• Intravitreal or sub-Tenon corticosteroid treatment in the study eye within the past 6 months.